Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications
- PMID: 39720352
- PMCID: PMC11665378
- DOI: 10.1016/j.ncrna.2024.11.006
Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications
Abstract
Lung cancer (LC) is one of the most common causes of cancer-related death worldwide. It has been demonstrated that the prognosis of current drug treatments is affected by a variety of factors, including late stage, tumor recurrence, inaccessibility to appropriate treatments, and, most importantly, chemotherapy resistance. Non-coding RNAs (ncRNAs) contribute to tumor development, with some acting as tumor suppressors and others as oncogenes. The phosphoinositide 3-kinase (PI3Ks)/AKT serine/threonine kinase pathway is one of the most important common targets of ncRNAs in cancer, which is widely applied to modulate the cell cycle and a variety of biological processes, including cell growth, mobility survival, metabolic activity, and protein production. Discovering the biology of ncRNA-PI3K/AKT signaling may lead to advances in cancer diagnosis and treatment. As a result, we investigated the expression and role of PI3K/AKT-related ncRNAs in clinical characteristics of lung cancer, as well as their functions as potential biomarkers in lung cancer diagnosis, prognosis, and treatment.
Keywords: Lung cancer; Molecular mechanisms; Non-coding RNAs; PI3K; Signaling pathway.
© 2024 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures







Similar articles
-
Relationship between the microRNAs and PI3K/AKT/mTOR axis: Focus on non-small cell lung cancer.Pathol Res Pract. 2022 Nov;239:154093. doi: 10.1016/j.prp.2022.154093. Epub 2022 Aug 28. Pathol Res Pract. 2022. PMID: 36183437 Review.
-
The potential role of circular RNAs -regulated PI3K signaling in non-small cell lung cancer: Molecular insights and clinical perspective.Pathol Res Pract. 2024 May;257:155316. doi: 10.1016/j.prp.2024.155316. Epub 2024 Apr 16. Pathol Res Pract. 2024. PMID: 38692125 Review.
-
Beyond the genome: lncRNAs as regulators of the PI3K/AKT pathway in lung cancer.Pathol Res Pract. 2023 Nov;251:154852. doi: 10.1016/j.prp.2023.154852. Epub 2023 Oct 4. Pathol Res Pract. 2023. PMID: 37837857 Review.
-
Targeting therapy of PI3K/AKT signaling pathway via non-coding RNAs in diabetic retinopathy.Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 1. doi: 10.1007/s00210-025-04093-z. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40167630 Review.
-
The emerging role of noncoding RNAs in the PI3K/AKT/mTOR signalling pathway in breast cancer.Pathol Res Pract. 2024 Mar;255:155180. doi: 10.1016/j.prp.2024.155180. Epub 2024 Jan 30. Pathol Res Pract. 2024. PMID: 38330621 Review.
References
-
- Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018;68(6):394–424. - PubMed
-
- Kahkesh S., Khoshnazar S.M., Gholinezhad Y., Esmailzadeh S., Hosseini S.A., Alimohammadi M., et al. The potential role of circular RNAs -regulated PI3K signaling in non-small cell lung cancer: molecular insights and clinical perspective. Pathol. Res. Pract. 2024;257 - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials